Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma von Tawbi, Hussein A, Schadendorf, Dirk, Lipson, Evan J, Ascierto, Paolo A, Matamala, Luis, Castillo Gutiérrez, Erika, Rutkowski, Piotr, Gogas, Helen J, Lao, Christopher D, De Menezes, Juliana Janoski, Dalle, Stéphane, Arance, Ana, Grob, Jean-Jacques, Srivastava, Shivani, Abaskharoun, Mena, Hamilton, Melissa, Keidel, Sarah, Simonsen, Katy L, Sobiesk, Anne Marie, Li, Bin, Hodi, F. Stephen, Long, Georgina V

Volltext

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer von Coutzac, Clélia, Jouniaux, Jean-Mehdi, Paci, Angelo, Schmidt, Julien, Mallardo, Domenico, Seck, Atmane, Asvatourian, Vahe, Cassard, Lydie, Saulnier, Patrick, Lacroix, Ludovic, Woerther, Paul-Louis, Vozy, Aurore, Naigeon, Marie, Nebot-Bral, Laetitia, Desbois, Mélanie, Simeone, Ester, Mateus, Christine, Boselli, Lisa, Grivel, Jonathan, Soularue, Emilie, Lepage, Patricia, Carbonnel, Franck, Ascierto, Paolo Antonio, Robert, Caroline, Chaput, Nathalie

Volltext

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Tr... von Ascierto, Paolo A, Mandalà, Mario, Ferrucci, Pier Francesso, Guidoboni, Massimo, Rutkowski, Piotr, Ferraresi, Virginia, Arance, Ana, Guida, Michele, Maiello, Evaristo, Gogas, Helen, Richtig, Erika, Fierro, Maria Teresa, Lebbè, Celeste, Helgadottir, Hildur, Queirolo, Paola, Spagnolo, Francesco, Tucci, Marco, Del Vecchio, Michele, Gonzales Cao, Maria, Minisini, Alessandro Marco, De Placido, Sabino, Sanmamed, Miguel F, Mallardo, Domenico, Curvietto, Marcello, Melero, Ignacio, Palmieri, Giuseppe, Grimaldi, Antonio M, Giannarelli, Diana, Dummer, Reinhard, Chiarion Sileni, Vanna

Volltext

The immune score as a new possible approach for the classification of cancer von Galon, Jérôme, Pagès, Franck, Marincola, Francesco M, Thurin, Magdalena, Trinchieri, Giorgio, Fox, Bernard A, Gajewski, Thomas F, Ascierto, Paolo A

Volltext

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma von Eggermont, Alexander M.M, Blank, Christian U, Mandala, Mario, Long, Georgina V, Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhail, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Maio, Michele, van den Eertwegh, Alfonsus J.M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul, Ibrahim, Nageatte, Marreaud, Sandrine, van Akkooi, Alexander C.J, Suciu, Stefan, Robert, Caroline

Volltext

The role of BRAF V600 mutation in melanoma von Ascierto, Paolo A, Kirkwood, John M, Grob, Jean-Jacques, Simeone, Ester, Grimaldi, Antonio M, Maio, Michele, Palmieri, Giuseppe, Testori, Alessandro, Marincola, Francesco M, Mozzillo, Nicola

Volltext

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial von Basset-Seguin, Nicole, Prof, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Kunstfeld, Rainer, Prof, Dréno, Brigitte, Prof, Mortier, Laurent, Prof, Ascierto, Paolo A, Prof, Licitra, Lisa, MD, Dutriaux, Caroline, MD, Thomas, Luc, Prof, Jouary, Thomas, MD, Meyer, Nicolas, MD, Guillot, Bernard, Prof, Dummer, Reinhard, Prof, Fife, Kate, MD, Ernst, D Scott, Prof, Williams, Sarah, MSc, Fittipaldo, Alberto, MD, Xynos, Ioannis, MD, Hansson, Johan, Prof

Volltext

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape von Emens, Leisha A, Ascierto, Paolo A, Darcy, Phillip K, Demaria, Sandra, Eggermont, Alexander M.M, Redmond, William L, Seliger, Barbara, Marincola, Francesco M

Volltext

The influence of diet on anti-cancer immune responsiveness von Soldati, Laura, Di Renzo, Laura, Jirillo, Emilio, Ascierto, Paolo A, Marincola, Francesco M, De Lorenzo, Antonino

Volltext

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma von Ribas, Antoni, Algazi, Alain, Ascierto, Paolo A., Butler, Marcus O., Chandra, Sunandana, Gordon, Michael, Hernandez-Aya, Leonel, Lawrence, Donald, Lutzky, Jose, Miller, Wilson H., Campbell, Katie M., Delafont, Bruno, Marshall, Shannon, Mueller, Nancy, Robert, Caroline

Volltext

Systemic Therapy for Melanoma: ASCO Guideline von Seth, Rahul, Messersmith, Hans, Kaur, Varinder, Kirkwood, John M, Kudchadkar, Ragini, McQuade, Jennifer Leigh, Provenzano, Anthony, Swami, Umang, Weber, Jeffrey, Alluri, Krishna C, Agarwala, Sanjiv, Ascierto, Paolo A, Atkins, Michael B, Davis, Nancy, Ernstoff, Marc S, Faries, Mark B, Gold, Jason S, Guild, Samantha, Gyorki, David E, Khushalani, Nikhil I, Meyers, Michael O, Robert, Caroline, Santinami, Mario, Sehdev, Amikar, Sondak, Vernon K, Spurrier, Gilliosa, Tsai, Katy K, van Akkooi, Alexander, Funchain, Pauline

Volltext

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial von Antonia, Scott J, Prof, López-Martin, José A, MD, Bendell, Johanna, MD, Ott, Patrick A, MD, Taylor, Matthew, MD, Eder, Joseph Paul, MD, Jäger, Dirk, MD, Pietanza, M Catherine, MD, Le, Dung T, MD, de Braud, Filippo, Prof, Morse, Michael A, Prof, Ascierto, Paolo A, MD, Horn, Leora, MD, Amin, Asim, MD, Pillai, Rathi N, MD, Evans, Jeffry, Prof, Chau, Ian, MD, Bono, Petri, MD, Atmaca, Akin, MD, Sharma, Padmanee, Prof, Harbison, Christopher T, PhD, Lin, Chen-Sheng, PhD, Christensen, Olaf, MD, Calvo, Emiliano, Dr

Volltext

PD-1 Blockade in Anaplastic Thyroid Carcinoma von Capdevila, Jaume, Wirth, Lori J, Ernst, Thomas, Ponce Aix, Santiago, Lin, Chia-Chi, Ramlau, Rodryg, Butler, Marcus O, Delord, Jean-Pierre, Gelderblom, Hans, Ascierto, Paolo A, Fasolo, Angelica, Führer, Dagmar, Hütter-Krönke, Marie Luise, Forde, Patrick M, Wrona, Anna, Santoro, Armando, Sadow, Peter M, Szpakowski, Sebastian, Wu, Hongqian, Bostel, Geraldine, Faris, Jason, Cameron, Scott, Varga, Andreea, Taylor, Matthew

Volltext

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial von Weber, Jeffrey S, Dr, D'Angelo, Sandra P, MD, Minor, David, MD, Hodi, F Stephen, MD, Gutzmer, Ralf, MD, Neyns, Bart, MD, Hoeller, Christoph, MD, Khushalani, Nikhil I, MD, Miller, Wilson H, MD, Lao, Christopher D, MD, Linette, Gerald P, MD, Thomas, Luc, MD, Lorigan, Paul, FRCP, Grossmann, Kenneth F, MD, Hassel, Jessica C, MD, Maio, Michele, MD, Sznol, Mario, MD, Ascierto, Paolo A, MD, Mohr, Peter, MD, Chmielowski, Bartosz, MD, Bryce, Alan, MD, Svane, Inge M, MD, Grob, Jean-Jacques, MD, Krackhardt, Angela M, MD, Horak, Christine, PhD, Lambert, Alexandre, PhD, Yang, Arvin S, MD, Larkin, James, FRCP

Volltext

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial von Ribas, Antoni, Prof, Puzanov, Igor, MD, Dummer, Reinhard, Prof, Schadendorf, Dirk, Prof, Hamid, Omid, MD, Robert, Caroline, Prof, Hodi, F Stephen, MD, Schachter, Jacob, Prof, Pavlick, Anna C, MD, Lewis, Karl D, MD, Cranmer, Lee D, MD, Blank, Christian U, MD, O'Day, Steven J, MD, Ascierto, Paolo A, Prof, Salama, April K S, MD, Margolin, Kim A, Prof, Loquai, Carmen, MD, Eigentler, Thomas K, MD, Gangadhar, Tara C, MD, Carlino, Matteo S, MBBS, Agarwala, Sanjiv S, Prof, Moschos, Stergios J, MD, Sosman, Jeffrey A, Prof, Goldinger, Simone M, MD, Shapira-Frommer, Ronnie, MD, Gonzalez, Rene, Prof, Kirkwood, John M, Prof, Wolchok, Jedd D, Prof, Eggermont, Alexander, Prof, Li, Xiaoyun Nicole, PhD, Zhou, Wei, PhD, Zernhelt, Adriane M, BS, Lis, Joy, BSN, Ebbinghaus, Scot, MD, Kang, S Peter, MD, Daud, Adil, Prof

Volltext

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma von Ascierto, Paolo A, Schadendorf, Dirk

Volltext

Immunological effects of BRAF+MEK inhibition von Ascierto, Paolo A., Dummer, Reinhard

Volltext

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer von Janjigian, Yelena Y, Bendell, Johanna, Calvo, Emiliano, Kim, Joseph W, Ascierto, Paolo A, Sharma, Padmanee, Ott, Patrick A, Peltola, Katriina, Jaeger, Dirk, Evans, Jeffry, de Braud, Filippo, Chau, Ian, Harbison, Christopher T, Dorange, Cecile, Tschaika, Marina, Le, Dung T

Volltext

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial von Eggermont, Alexander M M, Prof, Chiarion-Sileni, Vanna, MD, Grob, Jean-Jacques, Prof, Dummer, Reinhard, Prof, Wolchok, Jedd D, MD, Schmidt, Henrik, MD, Hamid, Omid, MD, Robert, Caroline, Prof, Ascierto, Paolo A, Prof, Richards, Jon M, MD, Lebbé, Céleste, Prof, Ferraresi, Virginia, MD, Smylie, Michael, MD, Weber, Jeffrey S, MD, Maio, Michele, MD, Konto, Cyril, MD, Hoos, Axel, MD, de Pril, Veerle, MSc, Gurunath, Ravichandra Karra, MD, de Schaetzen, Gaetan, PhD, Suciu, Stefan, PhD, Testori, Alessandro, MD

Volltext

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma von Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher D, Wagstaff, John, Schadendorf, Dirk, Ferrucci, Pier F, Smylie, Michael, Dummer, Reinhard, Hill, Andrew, Hogg, David, Haanen, John, Carlino, Matteo S, Bechter, Oliver, Maio, Michele, Marquez-Rodas, Ivan, Guidoboni, Massimo, McArthur, Grant, Lebbé, Celeste, Ascierto, Paolo A, Long, Georgina V, Cebon, Jonathan, Sosman, Jeffrey, Postow, Michael A, Callahan, Margaret K, Walker, Dana, Rollin, Linda, Bhore, Rafia, Hodi, F. Stephen, Larkin, James

Volltext